AI Health Index
Vendors · Behavioral Health AI · Wysa
W

Wysa pricing

Two product lines with opposite levels of commercial disclosure. The consumer offering is transparent: the basic conversational product is free and a premium subscription adds unlimited use plus access to human coaches, so a prospective user knows what costs money before engaging. The provider and enterprise line publishes nothing at all.

Wysa full profileWysa alternatives
Pricing terms

How Wysa pricing works

Pricing model
Partially disclosed. The consumer model is freemium with a subscription premium tier including human coaching. No unit of charge is stated for provider, payer, employer or health ministry deployments, and whether those price per patient, per member, per service or per license is unknown.
Implementation
Not disclosed. Wysa publishes no implementation, integration or onboarding fee for the provider products and no implementation timeline, although deployment into a national talking therapies service requires case management integration and satisfaction of national procurement assessment criteria.
Business associate agreement
Not disclosed as a template or posture. Compliance is claimed across four regimes named individually: the American health privacy framework where applicable, European and British data protection law, and Indian information technology and sensitive personal data rules. The company is registered with the British data protection regulator and meets the national health system data security toolkit standards. The American framework carries the qualifier where applicable: independent commentary observes the consumer application is not presented as covered for individual users, while enterprise and insurer deployments carry stronger obligations. Which regime governs a given configuration is not stated.

No pricing, unit of charge, per patient or per employee rate, minimum commitment or contract term is published for the health system, payer, employer or health ministry products the company describes as driving its growth, and those four buyer types imply four different commercial models. The company does not say whether the commissioned provider product is the same software the public receives free, and if so what the health system is paying for. Likely answers involve integration, clinical governance, reporting and the hybrid therapist workflow rather than the conversational agent itself, but nothing published says so.

Two further points bear on commercial evaluation. Funding is roughly $35 million in total, modest against a claimed six million plus users across more than 105 countries, and the most recent funding was a competitive research grant of roughly $7.2 million from a medical research charity in February 2026 rather than equity, which is scientific validation but a different signal from commercial traction. And because the consumer product is free, what the paid enterprise version measurably adds is the central commercial point, and it is not published. The contract term and exit provisions are not published either.

Compared on price

Wysa pricing against its alternatives

Published prices for Wysa and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.

All Wysa alternatives →

Questions

Wysa pricing, answered

How much does Wysa cost?

Two product lines with opposite levels of commercial disclosure. The consumer offering is transparent: the basic conversational product is free and a premium subscription adds unlimited use plus access to human coaches, so a prospective user knows what costs money before engaging. The provider and enterprise line publishes nothing at all.

Does Wysa charge an implementation fee?

Not disclosed. Wysa publishes no implementation, integration or onboarding fee for the provider products and no implementation timeline, although deployment into a national talking therapies service requires case management integration and satisfaction of national procurement assessment criteria.

Does Wysa offer a business associate agreement?

Not disclosed as a template or posture. Compliance is claimed across four regimes named individually: the American health privacy framework where applicable, European and British data protection law, and Indian information technology and sensitive personal data rules. The company is registered with the British data protection regulator and meets the national health system data security toolkit standards. The American framework carries the qualifier where applicable: independent commentary observes the consumer application is not presented as covered for individual users, while enterprise and insurer deployments carry stronger obligations. Which regime governs a given configuration is not stated.